Document Detail


Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial.
MedLine Citation:
PMID:  20843592     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Inhibition of the renin-angiotensin system is a widely accepted approach to treat immunoglobulin A (IgA) nephropathy, whereas the role of fish oils as a supplement is controversial. Tumor necrosis factor α (TNF-α) is considered to be involved in the pathophysiologic process of this disorder. Recent in vitro and clinical observations that wormwood can decrease TNF-α levels has led us to investigate the effect of wormwood as a supplement in patients with IgA nephropathy.
STUDY DESIGN: Pilot uncontrolled trial.
SETTING & PARTICIPANTS: 10 patients with biopsy-proven IgA nephropathy, normal kidney function, and a history of at least 3 months of proteinuria with protein excretion > 500 mg/d and < 3,500 mg/d despite ongoing dual renin-angiotensin system blockade.
INTERVENTION: The selected patients were given supplements of 1.8 g/d of thujone-free wormwood preparation for 6 months without discontinuing their renin-angiotensin system blockade.
OUTCOMES: Proteinuria and blood pressure after intervention compared with baseline values.
MEASUREMENTS: Monthly assessment of urine protein-creatinine ratio and blood pressure during the observation period.
RESULTS: Urine protein-creatinine ratio decreased significantly from 2,340 ± 530 to 315 ± 200 mg/g at the end of the supplementation period (P < 0.001) and was stable during the supplement-free follow-up of another 6 months. Estimated glomerular filtration rate and endogenous creatinine clearance were unchanged during the entire study period. There was a moderate, but significant, decrease (P < 0.002) in mean arterial blood pressure.
LIMITATIONS: Open uncontrolled trial including a small number of patients.
CONCLUSIONS: Thujone-free wormwood with its favorable safety profile can be an alternative supplement to manage proteinuria in patients with IgA nephropathy.
Authors:
Simone Krebs; Bilal Omer; Talib Noor Omer; Danilo Fliser
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2010-09-16
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  56     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2010-12-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1095-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Nuclear Medicine, University of Freiburg, Germany. simone.krebs@uniklinik-freiburg.de
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01126931
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Artemisia absinthium*
Blood Pressure / physiology
Creatinine / urine
Female
Glomerular Filtration Rate / physiology
Glomerulonephritis, IGA / drug therapy*,  physiopathology,  urine
Humans
Male
Phytotherapy*
Pilot Projects
Plant Preparations / therapeutic use*
Proteinuria / drug therapy*,  physiopathology,  urine
Renin-Angiotensin System / physiology
Treatment Outcome
Tumor Necrosis Factor-alpha / physiology
Young Adult
Chemical
Reg. No./Substance:
0/Plant Preparations; 0/Tumor Necrosis Factor-alpha; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of endothelial cell injury in thrombotic microangiopathy.
Next Document:  A policy case study of blood in Australia.